Cell & Gene Therapies: Five Years On – Real-World Data, Outcomes, and Evolution of Payers' Expectations

Speaker(s)

Alberto Briones, BSc, PhD, Lifescience Dynamics, London, UK

Presentation Documents

This session will explore the 5-year long-term outcomes of CAR-T therapies and other cell therapies to discuss:

  • The role of outcomes-based agreements (OBAs) in mitigating financial risk for payers and facilitating patient access to these therapies
  • Real-world evidence on the durability of responses and long-term safety profiles of CAR-T therapies
  • The implications of these outcomes for future access, pricing, and reimbursement decisions

This session will analyze whether these long-term outcomes justify continued access to CAR-T and cell therapies, considering both clinical results and cost-effectiveness data, and how OBAs may evolve to support sustainable access moving forward.

Sponsor: Lifescience Dynamics

Code

237

Topic

Clinical Outcomes